title: AbobotulinumtoxinA for reduction of glabellar lines in patients with skin of color: post hoc analysis of pooled clinical trial data.
abstract: BACKGROUND
  A paucity of research exists on the safety and efficacy of aesthetic medicine products in patients with skin of color (SOC).
  
  
  OBJECTIVE
  To compare the effectiveness and tolerability of abobotulinumtoxinA (BoNTA-ABO) for glabellar lines in a subpopulation of patients with SOC with that in white patients.
  
  
  METHODS
  This post hoc analysis considered pooled safety data from six clinical trials from which were derived a safety population (n = 1,869 white, n = 472 SOC), an efficacy population for a comparison of fixed-dose BoNTA-ABO 50 U in white patients (n = 216) and patients with SOC (n = 117), and an efficacy population for a comparison of BoNTA-ABO adjusted to muscle mass in white (n = 555) and patients with SOC (n = 160).
  
  
  RESULTS
  Adverse event rates were similar in white patients and patients with SOC. Onset of effect was similar in patients with SOC and white patients, but the response rate 30 days after treatment was greater in patients with SOC than in white patients.
  
  
  CONCLUSIONS
  Tolerability and effectiveness of treatment BoNTA-ABO for glabellar lines was similar in patients with SOC and white patients.
authors.affiliation: Society Hill Dermatology, Society Hill Dermatology, 932 Pine St., Philadelphia, PA 19107, USA. Drstaylor1@aol.com
authors.forename: Susan C
authors.initials: SC
authors.lastname: Taylor
authors.forename: Valerie D
authors.initials: VD
authors.lastname: Callender
authors.forename: Craig D
authors.initials: CD
authors.lastname: Albright
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Coleman
authors.forename: Robert A
authors.initials: RA
authors.lastname: Axford-Gatley
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Lin
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D044383:Black People; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003357:Cosmetic Techniques; D005006:Ethnicity; D015595:Skin Aging
chemical_list: C542869:abobotulinumtoxinA; D019274:Botulinum Toxins, Type A